Cross-Sector entity
clinical-trial is the sole category represented across all 1 tracked stories. Nature is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention He Jiankui, all published on August 1, 2026.
1 verified story tracked
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Nature is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention He Jiankui, all published on August 1, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering He Jiankui. Shared-story counts are live from our verified record — not editorial picks.
Shanghai Jiaotong University launches investigation
The university forms a working group to comprehensively investigate the clinical trial and the associated Nature paper.
Joint investigation report published
Science magazine and Retraction Watch release findings detailing the undisclosed death and ethical lapses, bringing the case to public attention.
Fatal gene-editing trial conducted
A young girl receives an experimental gene-editing treatment for a developmental-delay-linked genetic defect at Xinhua Hospital; she later dies, an outcome the ethics board deems treatment-related.
He Jiankui gene-edited babies scandal breaks
Chinese scientist He Jiankui announces the birth of the world’s first gene-edited babies, triggering global outrage and prompting China to tighten research regulations.
A young girl's death in an undisclosed gene-editing trial, funded by $860,000 from her parents, has triggered an investigation at Shanghai Jiaotong University. The case exposes critical ethics gaps in China's surging biopharma sector and raises alarms for investors, partners, and regulators worldwide.
Source: yahoo.com · egyptindependent.com
